352770 — Celestra Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Celestra, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	9,820	55,426	23,083	11,408	8,502
Cost of Revenue
Gross Profit	1,790	37,413	8,238	289	-1,182
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	22,074	32,499	33,858	47,248	53,837
Operating Profit	-12,254	22,927	-10,775	-35,840	-45,335
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-13,146	24,819	-10,122	-42,431	-47,089
Provision for Income Taxes
Net Income After Taxes	-13,147	15,853	-10,234	-42,399	-47,055
Minority Interest
Net Income Before Extraordinary Items
Net Income	-13,147	15,853	-10,177	-42,257	-46,925
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-13,147	14,204	-10,177	-42,257	-46,925
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-10,708	8,137	-6,442	-23,074	-14,746
Dividends per Share